MeMed  

7 Nahum Het St.
Tirat Carmel,  3508506

Israel
https://www.me-med.com
  • Booth: 2975

At MeMed, a leader in host response technologies, we decode the body’s complex signals into simple insights that improve people’s lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we have developed a point-of-need, rapid measurement platform called MeMed Key® to ensure timely availability of these novel tests during the clinician’s decision-making workflow. Run on the MeMed Key, MeMed BV® is an FDA-cleared host-immune response assay that can aid to distinguish between bacterial and viral infections, delivering fast and accurate results in 15 minutes from a serum or venous whole blood sample. This enables physicians to make faster, more informed decisions. MeMed BV was clinically validated in multiple multinational, double-blind clinical studies and real-world usage encompassing >20,000 patients and is also CE-IVD and AMAR cleared. Note: MeMed BV on whole blood is 510K cleared and currently available only for the US market.


 Press Releases

  • Collaboration to Add MeMed BV to Beckman Coulter Test Menu for use on
    Access Family of Immunoassay Analyzers

    BREA, CALIF. and HAIFA, Israel January 31, 2023 – Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, announced today a strategic partnership to jointly develop and commercialize the proven MeMed BV® test, a host immune response diagnostic that is able to distinguish between bacterial and viral infections for use on the Access Family of Immunoassay Analyzers.

    Symptoms of bacterial and viral infections are often clinically indistinguishable, which creates challenges for physicians when deciding to start treating patients with antibiotics or not. Unfortunately, this ambiguity in diagnosis can result in the underuse and overuse of antibiotics. Studies have shown that underuse of antibiotics for patients with a bacterial infection can reach 20%.[i] While overuse of antibiotics contributes to antimicrobial resistance, which is one of the top 10 global public health threats according to the World Health Organization.[ii] Today, antibiotic-resistant infections account for more than 700,000 deaths globally with the potential to increase to 10 million deaths by the year 2025.[iii] The development of new antibiotics is almost at a standstill, critically accelerating the need for increased antibiotic stewardship.iii  

    MeMed BV is a diagnostic test developed to address management of patients with acute infection in different clinical settings including Emergency Departments. The MeMed BV test uses machine learning to integrate measurements of three key host-immune proteins (TRAIL, IP-10, and CRP) into a score indicating the likelihood of bacterial or viral infections. This performance has been validated on MeMed’s compact immunoassay platform (MeMed Key®) by world class institutions in multi-national blinded validation studies as well as in real-world use, altogether in over 20,000 patients. MeMed BV on MeMed Key is US FDA cleared, CE-Marked and approved by the Israeli Ministry of Health.

    Under the terms of the agreement, Beckman Coulter has obtained the rights to develop and co-promote the proprietary MeMed BV test on its Access Family of Immunoassay Analyzers.

    “We are thrilled to be partnering with MeMed to make this novel test available to millions of patients through our Access Family of Immunoassay Analyzers. The ability to distinguish between bacterial and viral infections early in the diagnostic process has significant potential to impact patient care as well as combating antimicrobial resistance,” said Julie Sawyer Montgomery, President, Beckman Coulter. “Today’s investment reflects our commitment to continuously expand our IA menu through novel biomarker development, advance Emergency Medicine diagnostics alongside our MDW biomarker to measure infection severity and complement our microbiology innovations critical to identifying specific bacterial infection to optimize antibiotic therapies.”

    Dr. Eran Eden, MeMed’s CEO and co-founder, added: “Our vision for MeMed BV is that it becomes standard of care, enabling significant improvements in patient management to address the urgent global antimicrobial resistance threat. We believe forging a strategic alliance with an industry leader such as Beckman Coulter will expedite the realization of this vision and support better clinical, operational, and financial outcomes for healthcare systems globally.”

    About MeMed

    At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

    Follow and connect with MeMed via LinkedInTwitter, and Facebook.

    About Beckman Coulter. Inc.

    A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Beckman Coulter is part of the Danaher Corporation family of global science and technology companies. Headquartered in Brea, Calif., it has more than 11,000 global team members.

    Follow and connect with Beckman Coulter via LinkedInTwitter, and Facebook

    ###

    CONTACTS
    Jeff Tarmy

    Director of Global Public Relations
    Beckman Coulter Diagnostics
    jtarmy@beckman.com; +1-617-467-7537

    MeMed
    Consilium Strategic Communications

    MeMed@consilium-comms.com

    © 2023 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2023-XXXXX

    • Bacterial and viral infections are often clinically indistinguishable, leading to inappropriate patient management and antibiotic misuse
    • MeMed BV® is the first FDA-cleared host-immune response assay to accurately distinguish between the two in just 15 minutes

    PETAH TIKVA, Israel and HAIFA, Israel; April 18, 2023 – MeMed, a leader in the emerging field of advanced host-response technologies, and Schneider Children’s Medical Center, the only comprehensive, tertiary care hospital of its kind in Israel, today announce that clinical data from the independent, prospective Rosetta study, recently published in PLOS One, showed that the MeMed BV test provides an accurate diagnosis of bacterial versus viral infection and reduces Emergency Department (ED) physician error.

    The Rosetta study paper is called: Bacterial vs viral etiology of fever: A prospective study of host score for supporting etiologic accuracy of emergency department physicians.

    Fever is a common symptom in children presenting to the ED and owing to limitations of real-time decision-making, attending physicians often make presumptive diagnoses. This diagnostic uncertainty can result in sub-optimal patient management, including the precautionary use of antibiotics [1,2]. There is an urgent need for a rapid and accurate test that can assist physicians in distinguishing between bacterial and viral infections, enabling improved diagnosis and reducing the incidence of unnecessary antibiotic prescriptions.

    To address the unmet need, MeMed developed the world’s first US FDA-cleared advanced host-response technology that differentiates between bacterial and viral infection in 15 minutes – the MeMed BV test.

    The Rosetta study assessed the potential of MeMed BV to impact decision making and antibiotic stewardship in the ED by comparing its performance to physician’s etiological suspicion at patient presentation. The study enrolled 287 participants aged 3 months to 18 years, with respiratory tract infection or fever without source, in a tertiary care pediatric ED.

    MeMed BV showed high diagnostic accuracy, with an area under the curve (AUC) of 96%, sensitivity of 89%, specificity of 92%, and negative predictive value (NPV) of 99%. Furthermore, comparing physician suspicion to MeMed BV and to the reference standard, and assuming full adoption, the study found that MeMed BV has the potential to improve physician diagnosis and reduce errors by around two-fold, from 16% to 8%.

    Meirav Mor MD, Head of Hospital Infection Control and Senior ED Physician at Schneider Children's Medical Center, commented: “At Schneider, we’re dedicated to providing world-class pediatric care. In the Rosetta study, we assessed the impact of incorporating MeMed BV alongside our standard of care for children and discovered its significant potential for enhancing patient outcomes while also addressing the global antimicrobial resistance crisis.”

    Dr. Eran Eden, MeMed’s CEO and co-founder, added: “We’re delighted to present the latest findings from the Rosetta study, focused on pediatric patients that present to the emergency room with fever without a source or respiratory tract infections. The study adds to a growing body of evidence that underscores MeMed BV's reliability across diverse populations. This outcome serves as a testament to our unwavering commitment - to delivering tremendous clinical results, and we eagerly anticipate publishing additional in due course, exploring the use of MeMed BV in different patient populations.”

    About MeMed

    At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

    Follow and connect with MeMed via LinkedIn, Twitter, and Facebook.
     

    MeMed Contacts:
    Will Harris, VP Marketing, MeMed
    pr@me-med.com 

    Media relations contact:

    Consilium Strategic Communications MeMed@consilium-comms.com

    About Schneider Children’s Medical Center

    Schneider Children's Medical Center of Israel is the only comprehensive, tertiary care hospital of its kind in the country and in the Middle East, offering the full range of pediatric disciplines under one roof to all children from 0-18. Since its establishment in 1991, Schneider Children's has revolutionized the practice of pediatric medicine in the country and been recognized as one of the leading pediatric institutions in the world.

    Schneider derives its name from its founders and major benefactors, the late Irving and Helen Schneider from New York, who also promoted its legacy to serve as a Bridge to Peace between nations. Through this open-door policy, where all children irrespective of race, religion or nationality are treated, Schneider Children's receives patients from neighboring countries including the Palestinian Authority and Jordan, and from as far away as Africa, Asia and Eastern Europe.

    Schneider Children's comprises 250 beds, 43% of which are assigned to critical care (Intensive Care Units, Neonatology, Burns, etc.). The medical center serves as the national referral center for Hematology-Oncology, Endocrinology and Diabetes, Cardiology, and organ and bone marrow transplantation.

    Just for Children

    Schneider Children's is all about children. It utilizes a unique approach to pediatric medicine where children are treated as children and not as small adults. Since they have different emotional and physical resources for healing, Schneider Children’s utilizes a “whole-child-care” multidisciplinary approach, whereby treatment is integrated with emotional, psychological, educational and developmental care.

    Medical Excellence

    Schneider Children’s has led many firsts in Israel and the world: multi-organ transplantation, cardiac surgery in a 780gm preemie, heart valve replacement through catheterization, discovery of new genes for mental retardation, artificial pancreas trials, and innovative surgical and therapeutic techniques. Two physicians are recipients of Israel’s highest award: the Israel Prize for Medical Research.

    Academic Excellence

    Schneider Children's is a member of Clalit Health Services - the largest HMO in Israel - and its only pediatric center of 14 hospitals. Through its affiliation with the Sackler School of Medicine at Tel Aviv University, every department conducts the teaching and training of doctors, medical students, nurses and paramedical personnel. Over half its physicians serve on Sackler’s medical faculty, while some 14% hold the title of professor.

    Schneider Children’s Medical Center contact:

    Michal Konforti

    michalkon@clalit.org.il

    1. Poole NM, Shapiro DJ, Fleming-Dutra KE, Hicks LA, Hersh AL, Kronman MP. Antibiotic Prescribing for Children in United States Emergency Departments: 2009–2014. Pediatrics. 2019;143. pmid:30622156

    1. Leigh S, Grant A, Murray N, Faragher B, Desai H, Dolan S, et al. The Cost of Diagnostic Uncertainty: A Prospective Economic Analysis of Febrile Children Attending an NHS Emergency Department. BMC Med. 2019;17: 48. pmid:30836976

    • Opens up testing to decentralized settings including urgent care centers which see 100 million patient visits for potential infections in the US annually
    • Significant milestone towards making bacterial versus viral infection testing standard of care
    • Measurement of multiple low concentration proteins quickly in whole blood is notable new technological advance

    TIRAT CARMEL, Israel; BOSTON, MA, 19 July, 2023 – MeMed, a leader in the emerging field of advanced host response technologies, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on whole blood samples on the point-of-need MeMed Key® analyzer to help healthcare providers distinguish between bacterial and viral infections in 15 minutes.

    Through newly developed technology, MeMed BV on whole blood can accurately and quickly measure multiple proteins present in low concentrations from a small volume of whole blood. An earlier version of the test conducted on serum (cleared by the FDA in 2021) is being rolled out successfully in medical centers on the MeMed Key platform as well as on high throughput analyzers via partnerships with leading diagnostic companies.

    This new version of MeMed BV retains the exceptional performance of its serum counterpart but eliminates the need for clotting and spinning, enabling MeMed to approach decentralized settings in the US, such as urgent care centers, where minimal handling and maintenance are essential.

    Eran Eden, CEO of MeMed: “The FDA clearance of MeMed BV on whole blood is a significant milestone in our journey to make bacterial versus viral infection testing a standard of care. This enhancement to enable testing on whole blood allows for even easier use, faster results, and maintains the same level of performance, leading to improved patient care now being available across broader settings in the care continuum. The basis of physician prescription of unnecessary antibiotics is diagnostic uncertainty – is the patient presenting with a bacterial or a viral infection? The two are often clinically indistinguishable. By providing a rapid, reliable solution for differentiating between bacterial and viral infections, this test can help reduce the risk of unnecessary antibiotic prescriptions, one of the key drivers of antibiotic resistance.”

    Dr Sridevi Devaraj, Medical Director of Clinical Chemistry and Point of Care Testing at Texas Children’s Hospital, said: “This enhancement to the MeMed BV test is an exciting development. The fact that the test can now be carried out directly on whole blood means minimal handling and a reduced burden in the clinical setting alongside a bacterial versus viral decision with shorter patient waiting times. I anticipate that this will enhance both patient and physician satisfaction.”

    ---

    About MeMed

    At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. By leveraging expertise in host-response profiling and machine-learning algorithms, MeMed is creating a portfolio of tests that address tough clinical dilemmas.
    Follow and connect with MeMed via LinkedInTwitter, and Facebook.

    MeMed Contacts:
    Tal Avziz, VP Product & Marketing, MeMed
    pr@me-med.com

    Media relations contact:
    Consilium Strategic Communications
    MeMed@consilium-comms.com


 Products

  • MeMed Key & MeMed BV
    Bacterial and viral infections are often clinically indistinguishable and can lead to inappropriate patient management and antibiotic misuse. MeMed BV® is the first FDA-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections in just 15 minutes from serum or whole blood sameple....
     

  • Bacterial and viral infections are often clinically indistinguishable and can lead to inappropriate patient management and antibiotic misuse. MeMed BV® is the first FDA-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections in just 15 minutes from a serum or whole blood sample.

    MeMed Key® is a cutting edge, compact immunoassay platform that makes it possible to conduct highly sensitive, quick, multiplexed protein measurements that previously could only be done on large, expensive central lab equipment. Together, MeMed Key and MeMed BV help physicians make better decisions in the management of patients with acute infections.

    Our unique emphasis on quality and breadth of clinical evidence sets MeMed apart. MeMed BV performance has been validated in multi-national, double-blind clinical studies and real world settings enrolling over 20,000 subjects in Europe, Israel and the United States. These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes.


 Additional Info

We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth?
Yes
Countries of Interest
1. All Countries listed below